Vericel Co. (NASDAQ:VCEL – Get Free Report) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totalling 2,720,000 shares, a decline of 21.8% from the June 30th total of 3,480,000 shares. Based on an average daily volume of 367,200 shares, the short-interest ratio is currently 7.4 days.
Vericel Price Performance
NASDAQ VCEL traded down $1.22 on Monday, hitting $51.10. 111,168 shares of the stock traded hands, compared to its average volume of 462,836. The business’s fifty day moving average is $47.20 and its two-hundred day moving average is $46.55. Vericel has a 12 month low of $30.18 and a 12 month high of $54.08.
Vericel (NASDAQ:VCEL – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.16) earnings per share. Analysts anticipate that Vericel will post 0.11 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Vericel
Insiders Place Their Bets
In other Vericel news, insider Sean C. Flynn sold 1,474 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $45.84, for a total transaction of $67,568.16. Following the completion of the sale, the insider now directly owns 487 shares of the company’s stock, valued at approximately $22,324.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vericel news, insider Sean C. Flynn sold 1,474 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $45.84, for a total transaction of $67,568.16. Following the completion of the sale, the insider now directly owns 487 shares of the company’s stock, valued at approximately $22,324.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $52.18, for a total value of $782,700.00. Following the sale, the insider now directly owns 707 shares of the company’s stock, valued at $36,891.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,791 shares of company stock valued at $3,101,269. Corporate insiders own 5.20% of the company’s stock.
Institutional Investors Weigh In On Vericel
Several institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in shares of Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 220 shares in the last quarter. MCF Advisors LLC lifted its position in shares of Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares in the last quarter. Swiss National Bank lifted its position in shares of Vericel by 0.4% during the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock worth $4,656,000 after acquiring an additional 400 shares in the last quarter. CWM LLC lifted its position in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 504 shares in the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of Vericel during the first quarter worth $27,000.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
See Also
- Five stocks we like better than Vericel
- What is the Shanghai Stock Exchange Composite Index?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
- 3 Small Caps With Big Return Potential
- Pharma Giant’s Shares Up After Impressive Q2 Earnings Release
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.